2016
The Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer
Guo M, Luo G, Liu C, Cheng H, Lu Y, Jin K, Liu Z, Long J, Liu L, Xu J, Huang D, Ni Q, Yu X. The Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer. International Journal Of Molecular Sciences 2016, 17: 1090. PMID: 27399694, PMCID: PMC4964466, DOI: 10.3390/ijms17071090.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntigens, Tumor-Associated, CarbohydrateCarcinoma, Pancreatic DuctalChemotherapy, AdjuvantDisease-Free SurvivalErbB ReceptorsFemaleHumansImmunohistochemistryKaplan-Meier EstimateLymphatic MetastasisMaleMiddle AgedMultivariate AnalysisPancreatic NeoplasmsPredictive Value of TestsPrognosisProportional Hazards ModelsRetrospective StudiesConceptsAdjuvant chemotherapyPostoperative survivalEGFR statusOverall survivalSurvival benefitEGFR expressionPancreatic cancerProlonged median overall survivalResected pancreatic cancer patientsAssociated with improved survivalSurgically resected pancreatic cancerMedian overall survivalResectable pancreatic cancerSignificant survival benefitEpidermal growth factor receptorKaplan-Meier analysisPancreatic cancer patientsPancreatic cancer treatmentStudies of EGFRGrowth factor receptorResectable PDACAdjuvant therapyPrognostic significanceImproved survivalExpression subgroups
2014
Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS‐MS
Fitian A, Nelson D, Liu C, Xu Y, Ararat M, Cabrera R. Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS‐MS. Liver International 2014, 34: 1428-1444. PMID: 24661807, PMCID: PMC4169337, DOI: 10.1111/liv.12541.Peer-Reviewed Original ResearchMeSH Keywords12-Hydroxy-5,8,10,14-eicosatetraenoic AcidAmino AcidsBile Acids and SaltsCarcinoma, HepatocellularChromatography, High Pressure LiquidDicarboxylic AcidsGas Chromatography-Mass SpectrometryHepatitis CHumansHydroxyeicosatetraenoic AcidsLiver CirrhosisLiver NeoplasmsMetabolomeMetabolomicsMultivariate AnalysisROC CurveSphingosineTandem Mass SpectrometryXanthineConceptsPresence of HCCHepatocellular carcinomaUPLC/MS-MSHCC patientsMetabolic alterationsHepatitis C cirrhosisBile acid metabolismHallmarks of HCCMetabolomic profilingAcid metabolismReceiver operator characteristic analysisOperator characteristic analysisGlobal metabolic alterationsMetabolic pathway disturbancesC cirrhosisHCV cirrhosisHepatitis CMetabolic disturbancesHCC developmentSerum metabolomeHealthy volunteersEicosanoid pathwayCirrhosisPathway disturbancesBile acids
2012
CC genotype donors for the interleukin‐28B single nucleotide polymorphism are associated with better outcomes in hepatitis C after liver transplant
Firpi R, Dong H, Clark V, Soldevila‐Pico C, Morelli G, Cabrera R, Norkina O, Shuster J, Nelson D, Liu C. CC genotype donors for the interleukin‐28B single nucleotide polymorphism are associated with better outcomes in hepatitis C after liver transplant. Liver International 2012, 33: 72-78. PMID: 23107586, PMCID: PMC3518691, DOI: 10.1111/liv.12013.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntiviral AgentsBiopsyFemaleFloridaGenotypeHepatitis CHumansInterferonsInterleukinsKaplan-Meier EstimateLiver CirrhosisLiver TransplantationLogistic ModelsMaleMiddle AgedMultivariate AnalysisOdds RatioPolymorphism, Single NucleotideProportional Hazards ModelsRecurrenceRetrospective StudiesRisk AssessmentRisk FactorsTime FactorsTissue DonorsTreatment OutcomeConceptsSustained viral responseInterferon-based therapyLiver transplant patientsCC genotypeRecurrent HCVLiver transplantTransplant patientsIL-28B single nucleotide polymorphismInterleukin (IL) 28B single nucleotide polymorphismsAdult liver transplant patientsPost-transplant HCV recurrenceHepatitis C populationIL-28B genotypeIL-28B polymorphismsInterleukin 28B (IL28B) polymorphismsStrongest pretreatment predictorOverall clinical outcomeBetter treatment responseSingle nucleotide polymorphismsHCV recurrenceHCV patientsHCV therapyLiver transplantationHepatitis COverall survival